Barclays keeps Overweight rating on Indivior Pharmaceuticals shares
Barclays reaffirmed its Overweight rating on Indivior Pharmaceuticals. The update was reported by Dow Jones Newswires, citing Benzinga analyst ratings data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Barclays analysts have reaffirmed an Overweight rating on Indivior Pharmaceuticals, the pharmaceutical company. Dow Jones Newswires reported the move.
The information draws on analyst ratings data published by Benzinga on its website.
why it matters
Keeping an Overweight rating signals that Barclays still holds a positive view of the company's shares. Such reiterations are routine and usually have little effect on the stock unless they diverge from the wider analyst consensus.
tags
instruments
sources
- Indivior Pharmaceuticals Is Maintained at Overweight by Barclays — Dow Jones Newswires, 28 October 2026 at 15:51 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗